Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00281463 · ClinicalTrials.gov registry record · NA
Impact of Pushrim Activated Power Assist Wheelchairs on Mobility Among People With Tetraplegia
A NA study, sponsored by VA Pittsburgh Healthcare System.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT00281463: Completed NA study, sponsored by VA Pittsburgh Healthcare System.
NCT00281463 is a NA study that has completed, run by VA Pittsburgh Healthcare System. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00281463, a NA study, has completed, sponsored by VA Pittsburgh Healthcare System.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this three phase study is to evaluate a Pushrim Activated Power Assist Wheelchair (PAPAW). Phase I will examine whether the steady-state, metabolic energy efficiency for propelling a manual wheelchair with and without the device will be significantly different. In Phase II, wheelchair users will evaluate the PAPAW over activities of daily living course to determine its usability and acceptability and to identify areas for future development. Finally, in phase III, comparison of activities of daily living in the community will be made between the subjects when using their personal wheelchair and a PAPAW.
Interventions
- DEVICE Pushrim Activated Power Assist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2001-11 |
| Est. Completion | 2008-01 |
| Phase | NA |
What the finished NCT00281463 record still lists
NCT00281463 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Pushrim Activated Power Assist is the first listed.
NCT00281463 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00281463 about?
NCT00281463 is a clinical study titled "Impact of Pushrim Activated Power Assist Wheelchairs on Mobility Among People With Tetraplegia". The purpose of this three phase study is to evaluate a Pushrim Activated Power Assist Wheelchair (PAPAW). Phase I will examine whether the steady-state, metabolic energy efficiency for propelling a manual wheelchair with and without the device will be significantly different. In Phase II, wheelchair...
What is the current status of trial NCT00281463?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2001-11. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00281463?
The interventions under investigation include: Pushrim Activated Power Assist (DEVICE).
Who is sponsoring clinical trial NCT00281463?
This trial is sponsored by VA Pittsburgh Healthcare System, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00281463's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia